ArticleAmerican journal of cancer research2025
HECW2 knockdown suppresses the development of infantile hemangioma by inhibiting ALKBH5/LDHA axis-mediated glycolysis.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research Progress on Angiogenesis and Involution Mechanisms of Infantile Hemangioma and Its Regulation by Active Components ofInternational journal of molecular sciences · 2026Review
- Determinants of proliferation and involution in infantile hemangioma: macrophage crosstalk, endothelial plasticity, and metabolic rewiring.Frontiers in pediatrics · 2026Review
- Dynamic alterations in mFrontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2 (HECW2), a member of E3 ubiquitin ligase family, was identified as a hub gene in infantile hemangioma (IH). This study investigated the roles and mechanisms of HECW2 in IH development. Our investigation revealed that HECW2 was up-regulated in proliferative and involuting IH tissues compared with normal adjacent tissues. Hemangioma endothelial cells (HemECs) were isolated and transfected with over-expressed HECW2 or knockdown plasmids. Functional studies demonstrated that HECW2 over-expression facilitated proliferation, migration, invasion as well as inhibited apoptosis in HemECs. Furthermore, over-expressed HECW2 markedly promoted glycolysis in HemECs, as evidenced by increased glucose uptake, lactate production, and adenosine triphosphate (ATP) generation. In contrast, HECW2 knockdown showed the opposite results. Mechanistically, HECW2 regulated the ubiquitination of AlkB homolog 5 (ALKBH5), subsequently enhancing the expression of lactate dehydrogenase A (LDHA) through ALKBH5-mediated m6A demethylation of LDHA mRNA. HECW2 knockdown suppressed glycolysis and tumor-like cellular behaviors in HemECs, which were abrogated by LDHA over-expression. Additionally, in vivo validation using an IH xenograft mouse model demonstrated that HECW2 knockdown significantly suppressed tumor growth. These findings established HECW2 as a key regulator in IH progression through the regulation of ALKBH5/LDHA-mediated glycolysis, suggesting its potential as a therapeutic target for IH treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.